Nuzenio

Relmada Therapeutics Reports

Relmada Therapeutics Reports news intelligence with latest source-attributed stories, timeline, related explainers, connected entities, source diversity, and FAQ.

topic 9 latest news signals 6 publisher sources 100/100 entity strength

Latest news

Piper Sandler Reaffirms Their Buy Rating on Relmada Therapeutics (RLMD) - The Globe and MailThe Globe and Mail · Sat, 08 Aug 2026 15:30:00 GMT Relmada Therapeutics : Quarterly Report for Quarter Ending June 30, 2026 (Form 10-Q) - marketscreener.commarketscreener.com · Thu, 06 Aug 2026 22:44:53 GMT Relmada Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary - TradingViewTradingView · Thu, 06 Aug 2026 21:49:35 GMT Relmada Therapeutics (Nasdaq: RLMD) details Q2 2026 loss and NDV-01 Phase 3 path - Stock TitanStock Titan · Thu, 06 Aug 2026 20:41:35 GMT RELMADA THERAPEUTICS, INC. 2Q 2026: Net loss $12.9M, EPS $(0.11) — 10-Q Summary - TradingViewTradingView · Thu, 06 Aug 2026 20:36:00 GMT Relmada Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update - Yahoo FinanceYahoo Finance · Thu, 06 Aug 2026 20:05:00 GMT Press Release: Relmada Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update - MoomooMoomoo · Thu, 06 Aug 2026 20:05:00 GMT BlackRock (NYSE: BLK) discloses 7.0% beneficial stake in Relmada Therapeutics (RLMD) - Stock TitanStock Titan · Wed, 29 Jul 2026 07:00:00 GMT

Timeline

Sat, 08 Aug 2026 15:30:00 GMTPiper Sandler Reaffirms Their Buy Rating on Relmada Therapeutics (RLMD) - The Globe and Mail

Thu, 06 Aug 2026 22:44:53 GMTRelmada Therapeutics : Quarterly Report for Quarter Ending June 30, 2026 (Form 10-Q) - marketscreener.com

Thu, 06 Aug 2026 21:49:35 GMTRelmada Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary - TradingView

Thu, 06 Aug 2026 20:41:35 GMTRelmada Therapeutics (Nasdaq: RLMD) details Q2 2026 loss and NDV-01 Phase 3 path - Stock Titan

Thu, 06 Aug 2026 20:36:00 GMTRELMADA THERAPEUTICS, INC. 2Q 2026: Net loss $12.9M, EPS $(0.11) — 10-Q Summary - TradingView

Thu, 06 Aug 2026 20:05:00 GMTRelmada Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update - Yahoo Finance

Related explainers

ElectionsElection stories need careful handling because polls, turnout, legal challenges, and campaign claims can change quickly.HealthHealth stories help readers understand public-health signals, medical research, hospital systems, medicines, disease updates, and safety guidance.

Connected entities

Relmada Therapeutics7 live mentions RLMD6 live mentions Financial Results4 live mentions Provides Business Update4 live mentions The Globe3 live mentions Second Quarter3 live mentions Mail The Globe2 live mentions Mail2 live mentions Quarterly Report2 live mentions Quarter Ending June2 live mentions

FAQ

What does this page track?

Latest RSS headlines, source names, timestamps, related explainers, connected entities, and timeline signals for Relmada Therapeutics Reports.

Why might this page be noindex?

Nuzenio only indexes entity pages after enough useful source-attributed coverage and source diversity exists.

Where should readers verify facts?

Open the original publisher links from each story for full reporting, quotes, figures, images, corrections, and updates.

Source diversity

6 distinct publisher/source names are currently connected to this entity page.